PKA II

By Targets:	PKA (12) Akt (1) Biochemical Assay Reagents (1) CaMK (1) Casein Kinase (1) CRFR (1) GSK-3 (1) Liposome (2) Phosphodiesterase (PDE) (3) PKC (2) Ribosomal S6 Kinase (RSK) (1) ROCK (1)
By Research Areas:	Cancer (2) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (4) Neurological Disease (9)

Targets Recommended: PKA Photosystem II CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100530C

Sp-cAMPS sodium salt	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-156630

Ionizable lipid-1

Liposome Others

Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .

Ionizable lipid-1	Liposome	Others
Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .

HY-100530B

Sp-cAMPS	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-110005

Sp-cAMPS triethylamine	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-156630A

Ionizable lipid-1 hydrochloride	Liposome	Others
Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .

HY-120994B

Sp-8-CPT-cAMPS	PKA	Neurological Disease Inflammation/Immunology
Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .

HY-D0874

HEPPSO	Biochemical Assay Reagents	Others
HEPPSO is a zwitterionic buffer. The working pH range of HEPPSO buffer is 7.1-8.5. HEPPSO displays relatively high ability to bind copper(II), has a pK_a of 7.84 at 2.0 mM buffer concentration .

HY-100530A

Rp-cAMPS	PKA	Neurological Disease
Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .

HY-100530D

Rp-cAMPS sodium salt 1 Publications Verification	PKA	Neurological Disease
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor with K_i values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

HY-11012

TDZD-8 5+ Cited Publications GSK-3β Inhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of GSK-3β, with an IC₅₀ of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-100530

Rp-cAMPS triethylammonium salt	PKA	Neurological Disease
Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .

HY-16071

AT13148 2 Publications Verification	Akt PKA ROCK Ribosomal S6 Kinase (RSK)	Cancer
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

HY-120994

Rp-8-CPT-cAMPS sodium	PKA	Neurological Disease Inflammation/Immunology
Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .

HY-120994A

Rp-8-CPT-cAMPS	PKA	Neurological Disease Inflammation/Immunology
Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .

HY-N6732

K-252a Maximum Cited Publications 13 Publications Verification SF2370; Antibiotic K 252a; Antibiotic SF 2370
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-125957

A-3 hydrochloride	PKA Casein Kinase CaMK PKC	Others
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (K_i=4.3 µM), casein kinase II (K_i=5.1 µM) and myosin light chain kinase (MLCK) (K_i=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with K_i values of 47 µM and 80 µM, respectively .

HY-121197

Balanol Ophiocordin; Azepinostatin	PKA PKC	Others
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .

Cat. No.	Product Name	Type

HY-156630

Ionizable lipid-1

Drug Delivery

Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .

Ionizable lipid-1	Drug Delivery
Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .

HY-D0874

HEPPSO	Biochemical Assay Reagents
HEPPSO is a zwitterionic buffer. The working pH range of HEPPSO buffer is 7.1-8.5. HEPPSO displays relatively high ability to bind copper(II), has a pK_a of 7.84 at 2.0 mM buffer concentration .

HY-156630A

Ionizable lipid-1 hydrochloride	Drug Delivery
Ionizable lipid-1 (compound II-10) is an ionizable lipid (pKa=6.16) that can be used to prepare lipid nanoparticles (LNP) with bilayer structure .

Cat. No.	Product Name	Target	Research Area

HY-P2847

Urocortin II, mouse	CRFR	Metabolic Disease Endocrinology
Urocortin II, mouse is a potent and selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor with K_i values of 0.66 nM and ﹥100 nM for CRFR2 and CRFR1, respectively. Urocortin II, mouse activates CRF2 receptors in a cAMP/PKA- and Ca ²⁺/CaMKII-dependent manner.Urocortin II, mouse is expressed in discrete areas of the central nervous system, and activates central neurons involved in the processing of visceral sensory information, and in modulating autonomic outflow .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-121197

Balanol Ophiocordin; Azepinostatin	Structural Classification Natural Products Microorganisms Source classification	PKA PKC
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .

Cat. No.	Product Name	Application	Reactivity

HY-P80847

*Phospho-PKA* RII alpha (Ser99) Antibody** PRKAR2A; PKR2; PRKAR2; cAMP-dependent protein kinase type II-alpha regulatory subunit	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Pig
Phospho-PKA RII alpha (Ser99) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 46 kDa, targeting to Phospho-PKA RII alpha (Ser99). It can be used for WB,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Pig.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

PKA II

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Antibodies

Natural
Products